Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

111

Figures (1-6)

Tables (1-5)

Sum=190

Publishing Process of This Article

Item

Count

Browse

Download

Sum=13

Jul 15, 2024 (publication date) through Jul 17, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Jul 15, 2024; 15(7): 1518-1530
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1518

Table 4 Adverse effect counts, n (%)

Groups	Hypoglycemic reaction	Urinary tract infection	Gastrointestinal adverse effect	Respiratory distress	Vascular edema
Control group (n = 51)	3 (5.88)	2 (3.92)	3 (5.88)	1 (1.96)	2 (3.92)
Study group (n = 51)	2 (3.92)	1 (1.96)	1 (1.96)	2 (3.92)	3 (5.88)
χ²	0.210	0.343	1.041	0.343	0.210
P value	0.647	0.558	0.307	0.558	0.647

Citation: Yu PL, Yu Y, Li S, Mu BC, Nan MH, Pang M. Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety. World J Diabetes 2024; 15(7): 1518-1530
URL: https://www.wjgnet.com/1948-9358/full/v15/i7/1518.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i7.1518